Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Entry into a Material Definitive Agreement

Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item 1.01

Entry into a Material Definitive

On February 17, 2017 and March 3, 2017, Sun BioPharma, Inc. (the
Company) entered into Note Purchase Agreements (the Purchase
Agreements) with the investors named therein (the Investors) and
closed the transactions governed thereby. to the February 17,
2017 and March 3, 2017 Purchase Agreements, the Company issued to
the Investors $235,000 and $1,260,000, respectively, in original
principal amount of unsecured convertible promissory notes (the
Notes) to accredited investors for a total of $1,495,000 in gross

Amounts borrowed under the Notes are scheduled to mature on
December 1, 2018 and will bear interest at a rate of 5.0% per
annum. Principal and interest on the Notes are payable at
maturity. The Company may prepay the Notes in whole or in part at
any time without penalty or premium. The Notes may be converted
into shares of common stock or other securities of the Company
upon certain triggering events as described in the Notes,
including certain transactions and upon the request of a holder
of any Note. Upon the occurrence of certain events of default,
the Notes require the Company to repay the unpaid principal
amount of the Notes and any unpaid accrued interest. The Company
expects to use the net proceeds from the sales of the Notes for
working capital and general corporate purposes.

The foregoing descriptions of the Purchase Agreement and the
Notes are summaries and qualified by reference to the text of
such documents, which is attached hereto as Exhibits 10.1 and
10.2, respectively, and incorporated herein by reference.

Item 2.03

Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a

The information disclosed in Item 1.01 is incorporated by
reference into this Item.

Item 9.01 Financial Statements and


Form of Note Purchase Agreement, by and among the Company
and the Investors.

10.2 Form of Convertible Promissory Note.

About Sun BioPharma, Inc. (OTCMKTS:SNBP)

Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.

Sun BioPharma, Inc. (OTCMKTS:SNBP) Recent Trading Information

Sun BioPharma, Inc. (OTCMKTS:SNBP) closed its last trading session 00.00 at 2.50 with 1,000 shares trading hands.

An ad to help with our costs